Withdrawn application: Vijoice, alpelisib, Date of withdrawal: 30/10/2023, Initial authorisation
On 30 October 2023, Novartis withdrew its application for a marketing authorisation of Vijoice for the treatment of PIK3CA-related overgrowth spectrum (PROS), a genetic condition that causes a range of symptoms, including malformations and abnormal growth or tumours affecting several tissues, such as the skin, bones, blood vessels and brain.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
